Survival Outcomes and Tumor Molecular Profile Following Bicalutamide Neoadjuvant Therapy

NCT00418080 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: bicalutamide

Sponsor

University of L'Aquila